296 related articles for article (PubMed ID: 19287101)
1. Screening for early pancreatic ductal adenocarcinoma: an urgent call!
Lee MX; Saif MW
JOP; 2009 Mar; 10(2):104-8. PubMed ID: 19287101
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.
Urayama S
World J Gastroenterol; 2015 Feb; 21(6):1707-17. PubMed ID: 25684935
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS
World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695
[TBL] [Abstract][Full Text] [Related]
4. Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers.
Kaczor-Urbanowicz KE; Cheng J; King JC; Sedarat A; Pandol SJ; Farrell JJ; Wong DTW; Kim Y
Pancreas; 2020 Oct; 49(9):1141-1152. PubMed ID: 33003085
[TBL] [Abstract][Full Text] [Related]
5. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.
Yokoyama S; Higashi M; Kitamoto S; Oeldorf M; Knippschild U; Kornmann M; Maemura K; Kurahara H; Wiest E; Hamada T; Kitazono I; Goto Y; Tasaki T; Hiraki T; Hatanaka K; Mataki Y; Taguchi H; Hashimoto S; Batra SK; Tanimoto A; Yonezawa S; Hollingsworth MA
Oncotarget; 2016 Jul; 7(27):42553-42565. PubMed ID: 27283771
[TBL] [Abstract][Full Text] [Related]
7. The need for effective pancreatic cancer detection and management: a biomarker-based strategy.
Crawley AS; O'Kennedy RJ
Expert Rev Mol Diagn; 2015; 15(10):1339-53. PubMed ID: 26394703
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma.
Wang S; Chen X; Tang M
Tumour Biol; 2014 Sep; 35(9):9101-9. PubMed ID: 25027396
[TBL] [Abstract][Full Text] [Related]
9. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.
Halbrook CJ; Lyssiotis CA
Cancer Cell; 2017 Jan; 31(1):5-19. PubMed ID: 28073003
[TBL] [Abstract][Full Text] [Related]
10. Early detection and screening of pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Gonda TA; Saif MW
JOP; 2011 Mar; 12(2):83-5. PubMed ID: 21386626
[TBL] [Abstract][Full Text] [Related]
11. Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Saif MW
JOP; 2008 Jul; 9(4):398-402. PubMed ID: 18648129
[TBL] [Abstract][Full Text] [Related]
12. Caveolin-1: a marker for pancreatic cancer diagnosis.
Tanase CP
Expert Rev Mol Diagn; 2008 Jul; 8(4):395-404. PubMed ID: 18598222
[TBL] [Abstract][Full Text] [Related]
13. Identifying molecular markers for the early detection of pancreatic neoplasia.
Goggins M
Semin Oncol; 2007 Aug; 34(4):303-10. PubMed ID: 17674958
[TBL] [Abstract][Full Text] [Related]
14. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
15. Early detection of sporadic pancreatic cancer: summative review.
Chari ST; Kelly K; Hollingsworth MA; Thayer SP; Ahlquist DA; Andersen DK; Batra SK; Brentnall TA; Canto M; Cleeter DF; Firpo MA; Gambhir SS; Go VL; Hines OJ; Kenner BJ; Klimstra DS; Lerch MM; Levy MJ; Maitra A; Mulvihill SJ; Petersen GM; Rhim AD; Simeone DM; Srivastava S; Tanaka M; Vinik AI; Wong D
Pancreas; 2015 Jul; 44(5):693-712. PubMed ID: 25931254
[TBL] [Abstract][Full Text] [Related]
16. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
Singh P; Srinivasan R; Wig JD
Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas.
Wang Y; Gao J; Li Z; Jin Z; Gong Y; Man X
Int J Cancer; 2007 Dec; 121(12):2716-22. PubMed ID: 17708554
[TBL] [Abstract][Full Text] [Related]
18. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic ultrasound (EUS) and the management of pancreatic cancer.
Yousaf MN; Chaudhary FS; Ehsan A; Suarez AL; Muniraj T; Jamidar P; Aslanian HR; Farrell JJ
BMJ Open Gastroenterol; 2020 May; 7(1):. PubMed ID: 32414753
[TBL] [Abstract][Full Text] [Related]
20. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J
Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
